In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα
Benjamin Xiaoyi Li(Lee's Pharmaceutical (China)), Heyu Ni(St. Michael's Hospital), Zhongqiang Yang, Fang Qian, Hui Zhou(Shanghai International Studies University), Xiangrong Dai(Lee's Pharmaceutical (China)), Chuanbin Shen(Ocean University of China), Miguel A. D. Neves(Universidade do Porto), Reheman Adili(St. Michael's Hospital), Mandy Lokyee Li(Lee's Pharmaceutical (China)), Yfke Pasman(St. Michael's Hospital), Yiming Wang(St. Michael's Hospital), Yanan Zhao(First Affiliated Hospital of Wannan Medical College), Yongxiang Gao(University of Science and Technology of China), Maikun Teng(University of Science and Technology of China), Yan Hou(St. Michael's Hospital), Guangheng Zhu(St. Michael's Hospital), Xi Lei(St. Michael's Hospital), Alexandra H. Marshall(St. Michael's Hospital), Xiaohong Xu(Mayo Clinic), Tiffany Ni(St. Michael's Hospital), Jing Liu(Chinese Academy of Sciences), Eric G. Cerenzia(St. Michael's Hospital)
Cited by 45
Related Papers
Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies
|Thrombosis Journal|2016|196
Loss-of-Function Mutations in the PRPS1 Gene Cause a Type of Nonsyndromic X-linked Sensorineural Deafness, DFN2
|The American Journal of Human Genetics|2009|124
Defining the secondary structural requirements of a cocaine-binding aptamer by a thermodynamic and mutation study
|Biophysical Chemistry|2010|120
Activated NK cells cause placental dysfunction and miscarriages in fetal alloimmune thrombocytopenia
|Nature Communications|2017|113